Limited data exist on the effects of induction treatment in patients with newly diagnosed multiple myeloma (NDMM) and renal impairment (RI), who may also be ineligible for autologous stem cell transplant. This analysis investigated the impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on renal function in patients from the Connect® MM Registry based on transplant status. Eligible patients were aged ≥18 years with symptomatic MM diagnosed ≤2 months before enrollment. Patients in this analysis received front-line RVd for ≥3 cycles and were grouped by transplant status and baseline renal function. As of August 4, 2021, 344 transplanted and 289 non-transplanted patients had received RVd for ≥3 cycles at induction. Improved renal function was observed at 3, 6, and 12 months in patients with all severities of RI at baseline. In patients with >60 and ≤60 creatinine clearance mL/min at baseline, median progression-free survival was 49.4 months and 47.6 months in transplanted patients and 35.7 months and 29.1 months in non-transplanted patients, respectively. These results provide real-world evidence that patients with NDMM and RI who receive front-line RVd for ≥3 cycles may have improved renal function regardless of transplant status, with renal function no longer affecting the long-term outcome. Clinical trial information: NCT01081028.

关于诱导治疗对新诊断的多发性骨髓瘤 （NDMM） 和肾功能损害 （RI） 患者的影响的数据有限，这些患者也可能不符合自体干细胞移植的条件。该分析根据移植状态调查了来那度胺-硼替佐米-地塞米松 （RVd） 诱导对 Connect® MM Registry 患者肾功能的影响。符合条件的患者年龄为 ≥18 岁，在入组前 ≤2 个月诊断为有症状的 MM。该分析中的患者接受了 ≥3 个周期的一线 RVd，并按移植状态和基线肾功能分组。截至 2021 年 8 月 4 日，344 例移植患者和 289 例非移植患者在诱导时接受了 ≥3 个周期的 RVd。在基线时所有严重程度的 RI 患者在 3 、 6 和 12 个月时观察到肾功能改善。在基线时肌酐清除率 mL/min 为 >60 和 ≤60 的患者中，移植患者的中位无进展生存期分别为 49.4 个月和 47.6 个月，非移植患者的中位无进展生存期分别为 35.7 个月和 29.1 个月。这些结果提供了真实世界的证据，无论移植状态如何，接受一线 RVd 治疗 ≥3 周期的 NDMM 和 RI 患者都可能肾功能得到改善，肾功能不再影响长期结局。临床试验信息：NCT01081028。